PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report)’s stock price traded up 5.9% during trading on Monday . The stock traded as high as $0.7982 and last traded at $0.7412. 97,670 shares were traded during trading, an increase of 1,006% from the average session volume of 8,831 shares. The stock had previously closed at $0.70.
PharmaCyte Biotech Trading Up 5.9%
The stock’s 50 day simple moving average is $0.87 and its two-hundred day simple moving average is $0.91.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Further Reading
- Five stocks we like better than PharmaCyte Biotech
- The buying spree that no one is talking about
- How to collect $500-$800 weekly (BlackRock’s system)
- Trump’s AI Secret: 100X Faster Than Nvidia
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Your Bank Account Is No Longer Safe
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
